Iobion Informatics and Affymetrix Enter Co-Marketing Agreement
Iobion Informatics announced Monday that its software product, ArrayAssist, has been designated an Affymetrix premier application, a new category Affymetrix has devised in a marketing effort to promote tools that work with its GeneChip-brand platform.
ArrayAssist is a desktop application for the analysis of Affymetrix GeneChip microarray data for the research biologist.
Iobion Informatics of La Jolla, Calif., is an affiliate of Stratagene.
India Proposes Plant Genome Research And Hyderabad Nanotechnology Center
India this week announced two forward moves in genomics with the unveiling of a Plant Genome Research road map, and in Hyderabad, the planned organization of a nanotechnology center for cellular and molecular biology, according to news reports.
The Indian government disclosed the Plant Genome Research road map at the Indian Science Congress, held in Chandigarh, according to the BBC. It involves using plant genomics to design genetically modified crops that can better feed India’s growing population, such as a high-protein potato, Assis Datta, Director of the National Center for Plant Genome Research, told the BBC.
Meanwhile, the CCMB in Hyderabad is seeking financing of about 280 million rupees, or $6.14 million, for the nanotechnology center, according to India’s Financial Express. The nanotechnology center is being designed to combine scientists from biology, physics, and chemistry, to study biology for seeing the genetic material in DNA, and to use microarrays or lab-on-a-chip devices. Part of the proposal includes setting up a 600 MHz imaging facility, the news report said.
Ciphergen Partners with GE On ProteinChip Service in Asia
The Medical Systems’ Trade and Development unit of General Electric will become Ciphergen Biosystems’ post-sale services partner for its ProteinChip systems for hospitals in China, Hong Kong, and Taiwan, the companies said in December.
Ciphergen and GE Medical Systems have been working together in China on an “informal basis” for the past year, and have now established a “formal,” multi-year services agreement, according to a statement.
Financial and other terms of the agreement were not disclosed by the companies.
Exiqon, Integrated DNA Technologies Ink Locked Nucleic Acid Licensing Deal
Denmark’s Exiqon has licensed certain rights to its locked nucleic acid technology to Integrated DNA Technologies (IDT), the companies announced this week.
Financial terms of the arrangement were not disclosed.
Under the terms of the deal, IDT has non-exclusive rights to manufacture and sell locked nucleic acid oligonucleotides for the genomics research market and will receive access to certain Exiqon knowledge related to the technology.
According to the companies, a locked nucleic acid is a proprietary nucleic acid analog that is easily incorporated into synthetic DNA oligos. Locked nucleic acid probes, they added, have successfully been used in both RT-PCR-based expression profiling and SNP genotyping assays, as well as in expression microarrays and siRNA oligos for target validation.
Lynx Completes $4M Private Stock Placement
Lynx Therapeutics said it has completed a $4 million private financing of common stock and warrants for common stock. The financing included the sale of 800,000 newly issued shares of common stock at $5.00 per share and the issuance of warrants to purchase 200,000 shares of common stock at an exercise price of $6.25 per share. Kevin Corcoran, Lynx’s president and CEO, said the company plans to use the financing to expand the commercial usage of its MPSS (Massively Parallel Signature Sequencing) technology. Lynx completed a $3 million common stock placement in September.
Pasteur Institute to Open Korean Branch
The Pasteur Institute is planning to open a branch in Korea in February, according to news reports.
The Korea Herald said that the Pasteur Institute will open in the Korea Institute of Science and Technology in Seoul before relocating to its own site in five years. Pasteur Institute Korea has adopted the motto “Genome to Drug,” reflecting its goal to advance gene studies into drug development, the paper added.
The branch will be headed by Ulf Nherbass, head cell biology researcher at the Pasteur Institute in France, and is expected to receive about €100 million in funding over the next 10 years from the Korean Science Ministry, the Korea Herald added.